CEP
VIR icon

Chicago Equity Partners’s Vir Biotechnology VIR Stock Holding History

Chicago Equity Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$474K Buy
+13,829
New +$372K 0.05% 437

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Chicago Equity Partners's VIR Position: Q1 2020 in Review

Chicago Equity Partners opened a new position in Vir Biotechnology (VIR) in Q1 2020: 13,829 shares worth $474K. The stake represents 0.05% of the portfolio and ranks #437 among its holdings.

61 funds tracked by Wall St. Rank hold VIR as of Q1 2020.

  • Chicago Equity Partners held 13,829 shares of Vir Biotechnology worth $474K as of Q1 2020.
  • Vir Biotechnology was a new Chicago Equity Partners position in Q1 2020.
  • Vir Biotechnology made up 0.05% of Chicago Equity Partners's portfolio in Q1 2020, its #437 holding.
  • 61 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.